JMP reiterates Lifecore at strong buy

Lifecore Biomedical, Inc. was reiterated by JMP Securities analyst Anthony Ostrea at a strong buy and an $18 price target following quarterly U.S. dental implant checks indicate a robust outlook for the next 12 months. According to the analyst, those using Lifecore's implants had strong demand with steady penetration of Prima. Ostrea believes Lifecore's revenue will be in line with his estimated $15 million when announced on Oct. 17. Shares of the Chaska, Minn.-based biotechnology company were up 61 cents, or 4.14%, at $15.34. (Nasdaq: LCBM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.